NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEGLUROMET is a fixed-dose combination tablet of ertugliflozin (an SGLT2 inhibitor) and metformin hydrochloride for oral treatment of type 2 diabetes mellitus. The combination leverages two complementary mechanisms: ertugliflozin increases urinary glucose excretion while metformin reduces hepatic glucose production and improves insulin sensitivity. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
$0.001BPart D
Peak4.5 years to LOEProduct is at peak lifecycle with modest Part D spending ($1M in 2023) and ~2,400 claims annually, suggesting a mature, stable franchise with limited growth trajectory.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on SEGLUROMET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.